← Leaderboards
Michael A Mokowitz
Massachusetts General Hospital
$1,341,872
Attributed
$1,341,872
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$1,341,872 · 1
By mechanism
R01$1,341,872 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Michael A Schwarzschild$27,249,495
- Eng H. Lo$32,456,318
- Dimitri Krainc$24,610,296
- M Flint Beal$24,698,686
- Michael A Moskowitz$13,795,692
Others in their field
Top investigators on “Antihypercholesterolemic Agent”
- Ronald M Krauss · University Of Calif-Lawrenc Berkeley Lab$10,346,841
- Barry Davis · University Of Texas Hlth Sci Ctr Houston$6,259,000
- Beatrice A Golomb · University Of California San Diego$5,517,551
- Patricia F Coogan · Boston University Medical Campus$2,532,527
- Bruce M Psaty · University Of Washington$2,093,698
- James Kuang-Jan Liao · Brigham And Women'S Hospital$2,013,135
Research focus
Antihypercholesterolemic AgentChemopreventionDisease /Disorder ModelEnzyme ActivityEnzyme Induction /RepressionEnzyme InhibitorsGene TargetingGenetically Modified AnimalsHmg Coa ReductasesHypercapniaLaboratory MouseNeuropharmacologyNeuroprotectantsNitric Oxide SynthaseStrokeVascular EndotheliumVasodilators
Grant awards (4)
NOVEL USE OF HMG COA REDUCTASE INHIBITORS IN STROKE$350,485
R01 · FY2003 · HL
NOVEL USE OF HMG COA REDUCTASE INHIBITORS IN STROKE$340,276
R01 · FY2002 · HL
NOVEL USE OF HMG COA REDUCTASE INHIBITORS IN STROKE$330,365
R01 · FY2001 · HL
NOVEL USE OF HMG COA REDUCTASE INHIBITORS IN STROKE$320,746
R01 · FY2000 · HL